Author

Sundara Moorthi Nainar Murugesan

Institution: Biocon (India)

Observed institutions: Lupin Pharmaceuticals (India), Biocon (India)

ORCID: 0000-0002-9952-487X

Observed ORCID: 0000-0002-9952-487X

OpenAlex ID: A5091362192

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US ‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE ‐1 ( Recombinant Human INsulin Equivalence‐1 ) study

2022 · Leona Plum‐Mörschel, Gursharan Singh, et al. · Diabetes Obesity and Metabolism · 8

An open‐label, multiple ascending dose trial of orally administered insulin Tregopil in patients with type 1 diabetes mellitus to evaluate its pharmacokinetics, pharmacodynamics, safety and tolerability

2025 · Esther Latres, Leona Plum‐Moerschel, et al. · Diabetes Obesity and Metabolism · 3

Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer

2023 · Joel S. Owen, Russell J. Rackley, et al. · European Journal of Drug Metabolism and Pharmacokinetics · 3

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US ‐licensed Humulin® N formulation in healthy subjects: Results from the RHINE ‐2 (Recombinant Human INsulin Equivalence‐2) study

2023 · Grit Andersen, Gursharan Singh, et al. · Diabetes Obesity and Metabolism · 1

Evaluation of Inter-Occasion Variability on Trospium Pharmacokinetics in Healthy Human Subjects using Non-Compartment Methods

2014 · Sundara Moorthi Nainar Murugesan · Journal of Bioequivalence & Bioavailability · 1

Author response for "An open‐label, multiple ascending dose trial of orally administered insulin Tregopil in patients with type 1 diabetes mellitus to evaluate its pharmacokinetics, pharmacodynamics, safety and tolerability"

2025 · Esther Latres, Leona Plum‐Moerschel, et al. · Publons reviews and discussion

Author response for "Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin N with US ‐licensed Humulin® N formulation in healthy subjects: Results from the RHINE ‐2 (Recombinant Human INsulin Equivalence‐2) study"

2023 · Grit Andersen, Gursharan Singh, et al. · Publons reviews and discussion

Author response for "Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US‐licensed Humulin® 70/30 formulation in healthy subjects: Results from the RHINE‐3 (Recombinant Human INsulin Equivalence‐3) study"

2022 · Leona Plum‐Morschel, Oliver Klein, et al. · Publons reviews and discussion

Author response for "Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US ‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE ‐1 (Recombinant Human INsulin Equivalence‐1) study"

2021 · Leona Plum‐Mörsch el, Gursharan Singh, et al. · Publons reviews and discussion

Population pharmacokinetics (Pop PK) of MYL-1402O (a proposed biosimilar to bevacizumab) and reference product (Avastin) in patients with nonsquamous non-small cell lung cancer (nsNSCLC).

2021 · Joel Owen, Russell J. Rackley, et al. · Journal of Clinical Oncology

Works count: 10

Citation count: 16

H-index: 3

I10-index: